QT prolongation risk with antiemetics during COVID 19 treatment

dc.contributor.authorAksoy, Nilay
dc.contributor.authorSancar, Mesut
dc.date.accessioned2021-05-15T12:49:26Z
dc.date.available2021-05-15T12:49:26Z
dc.date.issued2021
dc.departmentEczacılık Fakültesien_US
dc.description.abstractAntiemetics gained an active position in the COVID-19 pandemic as a medical approach to suppressing SARS-CoV-2-induced nausea and vomiting as well as balance side effects from medications in use. Proposed treatments for COVID-19 initiate a concern in regard to the influential impact on cardiotoxicity and prolonged QT intervals. Antiemetic agents pose an additional risk through the prolongations of QT intervals when medication is used concurrently with COVID-19 pharmacological therapies.en_US
dc.identifier.doi10.1111/ijcp.14041
dc.identifier.issn1368-5031
dc.identifier.issue5en_US
dc.identifier.pmid33887871
dc.identifier.scopus2-s2.0-85104598563
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1111/ijcp.14041
dc.identifier.urihttps://hdl.handle.net/20.500.12939/1010
dc.identifier.volume75en_US
dc.identifier.wosWOS:000644132400065
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAksoy, Nilay
dc.language.isoen
dc.publisherBlackwell Publishing Ltden_US
dc.relation.ispartofInternational Journal of Clinical Practice
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCovid-19en_US
dc.subjectQTen_US
dc.subjectMedicalen_US
dc.titleQT prolongation risk with antiemetics during COVID 19 treatment
dc.typeLetter

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Int J Clinical Practice - 2021 - Aksoy - QT prolongation risk with antiemetics during COVID 19 treatment.pdf
Boyut:
219.91 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text